- Published Articles
- In the Press
- Press Releases
Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
March 8th, 2013
NAD Decision Did Not Support Class Action Suit Against Bayer
On February 11, 2013, Judge Stanley R. Chesler, United States District Judge for the District of New Jersey, held in an unpublished decision that a report from the National Advertising Division of the Better Business Bureau ("NAD") provided insufficient support for class action plaintiffs' claims of false advertising and misrepresentation under the New Jersey Consumer Fraud Act ("NJCFA").
In early 2012, the NAD issued a report finding unreliable the sole study Bayer Healthcare, LLC ("Bayer") offered to support labeling claims for its calcium supplement product, Citrical SR. The NAD recommended Bayer discontinue any and all labeling claims based on the evidence provided by this study.
Class action plaintiffs filed suit soon after, claiming that Bayer's Citracal SR advertising was false in violation of the NJCFA. Plaintiffs argued that the NAD''s findings provided sufficient factual basis to support claims that Bayer''s advertising was false and misleading.
Bayer moved to dismiss plaintiffs' complaint, and the court granted Bayer's motion. See Gaul et al v. Bayer Healthcare, LLC, No. 12-5110, 2013 U.S. Dist. LEXIS 22637 (D.N.J. February 11, 2013). In his decision, Judge Chesler explicitly stated that "unreliability" for purposes of claim substantiation was a "very big leap" from a finding of "falsity" in the consumer class action context, and thus plaintiffs had not met their burden of pleading a violation of the NJCFA.
For advertisers who rely on NAD to adjudicate their disputes with competitors, the court's decision, albeit unpublished and therefore of limited precedential value, may help parties feel more confident about participating in this useful alternative to litigation. This is good news too for regulators who tout the self-regulatory forum as an important tool for keeping advertisers in line.
If you have questions about the Gaul decision or any other advertising or litigation matter, please contact Terri J. Seligman at 212.826.5580 or firstname.lastname@example.org, Hannah Taylor at 212.705.4849 or email@example.com, or any other member of the Frankfurt Kurnit Advertising or Litigation groups.
Other Advertising Law Alerts
New Low-Budget Waiver is Now Available for Digital Commercial Productions
Advertisers and agencies that are signatories to the SAG-AFTRA Commercials Contract can now take advantage of a new waiver issued by SAG-AFTRA and the Joint Policy Committee on Broadcast Talent Union Relations when producing low-budget digital commercials.
November 10 2017
FTC Updates Endorsement Guide FAQs and Settles First-Ever Action Against Individual “Influencers”
Recent developments demonstrate the FTC's continued interest in social media endorsements.
September 11 2017
FTC Announces Reforms to Its Investigative Process
Recently, the FTC announced a set of internal reforms intended to improve the process by which the Commission investigates unfair, deceptive and fraudulent business practices. The reforms relate to the Civil Investigative Demands ("CID") that the FTC's Bureau of Consumer Protection issues to request information from investigation targets.
September 7 2017